Search

for
Search:

Glossary Brepocitinib

medication that inhibits enzymes involved in inflammation

Brepocitinib is a medication that inhibits certain enzymes known as Janus kinases (JAKs) and tyrosine kinase 2 (TYK2). These enzymes play a role in the inflammatory process, and by blocking them, Brepocitinib can help reduce inflammation and is being studied for the treatment of autoimmune conditions like alopecia areata, psoriasis, and other inflammatory diseases.

Research

5 / 148 results

research A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results

138 citations , March 2021 in “Journal of the American Academy of Dermatology”

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

research Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers

36 citations , December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.

research Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial

20 citations , December 2021 in “Journal of the American Academy of Dermatology”

This study found that the oral JAK inhibitors ritlecitinib and brepocitinib were effective in maintaining hair regrowth in alopecia areata with continuous use, though efficacy decreased after withdrawal.

research A phase 2a trial of brepocitinib for cicatricial alopecia

17 citations , October 2024 in “Journal of the American Academy of Dermatology”

In this study, brepocitinib was found to significantly reduce inflammatory biomarker CCL5 expression and improve clinical severity by week 24, while maintaining a favorable safety profile.

research 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers

July 2024 in “Journal of Investigative Dermatology”

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

View more "brepocitinib" in research →

Learn

— no results

Community Join

— no results

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →